drugset
drugset / Trial / NCT02337764

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

NCT02337764 ↗

Phase 3 Completed 222 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.

Timeline

Start
2015-02-03
Primary completion
2016-09-29
Completion
2016-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule 1 mg Oral

Indications

Parkinson disease